Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04624633 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 12, 2020
Last Update Posted : March 19, 2024
|
Sponsor:
Jennifer R. Brown, MD, PhD
Collaborators:
AstraZeneca
TG Therapeutics, Inc.
Information provided by (Responsible Party):
Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Estimated Primary Completion Date : | January 1, 2025 |
| Estimated Study Completion Date : | January 1, 2030 |